A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
← catalyst calendarNCT07752875 · readout in 2,265 d
Sponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
250estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-12-01 | estimated | When the study began enrolling |
| Primary completion | 2032-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Esophageal Cancer
- Breast Cancer
- Endometrial Cancer
- Head and Neck Cancer
- Pancreatic Cancer
- Locally Advanced Unresectable or Metastatic Solid Tumor
Intervention
- Drug: LG00313112
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Number of participants with dose-limiting toxicities (DLTs)
measured Up to 21 days after treatment
Phase 1: Frequency of treatment-emergent adverse events (TEAEs)
measured Up to 12 months after treatment initiation
Phase 1: Frequency of serious adverse events (SAEs)
measured Up to 12 months after treatment initiation
Phase 2: objective response rate (ORR)
measured Up to 12 months after treatment initiation
Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed